Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoChoose your plan
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KMEDIUM RiskNeutral

Rallybio Corporation

rallybio.com
Filed: Mar 31, 2026New Haven, ConnecticutCIK: 1739410
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Rallybio Corporation's Chief Medical Officer Steven Ryder, M.D. departed effective March 31, 2026, after serving since January 2019. This leadership transition may impact the company's medical strategy and clinical development initiatives during the search for a replacement.

Key Takeaways

Steven Ryder, M.D. has immediately departed from his role as Chief Medical Officer after approximately 7 years of tenure

A separation agreement has been established providing severance payments and benefits per his prior employment terms

2 more takeaways

Filing Overview

Form Type8-K
Filing DateMar 31, 2026
Item5.02
CategoryExecutive Change
CIK1739410
Accession #0001739410
Risk LevelMEDIUM
SentimentNeutral
Signalrisk
Topics
executive departureleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings